A new study from the University of Pittsburgh Center for Vaccine Research published in the Journal of Experimental Medicine describes a previously unappreciated role for a class of immune cells in the early stages of tuberculosis (TB) infection.

Scientists at the University of Pittsburgh School of Medicine have discovered a tuberculosis (TB) vaccination strategy that could prevent the leading cause of death among people worldwide living with HIV.

PITTSBURGH – A high proportion of multidrug-resistant tuberculosis (TB) cases can be cured in conflict-affected communities with molecular diagnostics, shorter treatment periods and socioeconomic incentives, according to the results of a large, long-term study in the Democratic Republic of Congo (DRC) led by the University of Pittsburgh Graduate School of Public Health and Stellenbosch Universityin South Africa, in collaboration with the DRC National Tuberculosis Program.